Search - tctmd.com

Displaying 101 - 118 of 118

Sort: Relevancy | Date

News Daily News

Timing and Dose Matters When It Comes to Statin Therapy Before CABG Surgery

Michael O'Riordan

March 16, 2017

News Conference News CRT 2017

Higher Mortality Among TAVR Patients With Atrial Fibrillation Treated With Triple Therapy

Michael O'Riordan

February 20, 2017

News Features

Be It Resolved: How Alcohol Harms or Helps the Heart Remains Controversial—and Confusing

Shelley Wood

January 04, 2017

News Daily News

Best Anticoagulant in the TAVR Patient With A-fib? Small Study Makes Case for Apixaban

Michael O'Riordan

January 03, 2017

News Features

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

Shelley Wood

December 30, 2016

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

News Features

Repaso del Año: Los Médicos Eligen las Noticias Más Importantes de 2016 en Cardiología Intervencionista y Más

Shelley Wood

December 30, 2016

News Daily News

Avoid Simvastatin, Lovastatin in Dabigatran-Treated Patients, Analysis Suggests

Todd Neale

November 24, 2016

An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Presentation AHA 2016

PIONEER Trial: An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy

Presenter: Michael Gibson

November 15, 2016

News Conference News AHA 2016

Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI

Todd Neale

November 14, 2016

News Daily News

FDA: ROCKET AF Results Not Affected by Faulty INR Testing in Warfarin Arm

Michael O'Riordan

October 11, 2016

News Daily News

Addition of Biomarkers May Fine Tune Risk Stratification in Atrial Fibrillation

Michael O'Riordan

October 07, 2016

News Conference News ESC 2016

NOACs as Effective as Warfarin for Reducing Stroke, but Apixaban and Dabigatran May Carry Lower Bleeding Risk: Registry

Michael O'Riordan

August 28, 2016

News Daily News

Increased Risk of In-Hospital Complications, Including Mortality, Among A-fib Patients Undergoing PCI

Michael O'Riordan

August 24, 2016

News Daily News

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Michael O'Riordan

August 18, 2016

News Daily News

Study Provides More Evidence That Having A-fib Ups Risk of Developing Dementia

L.A. McKeown

July 19, 2016

News Daily News

New A-fib Performance and Quality Measures Emphasize Shared Decision-Making, Inpatient and Outpatient Care

Michael O'Riordan

June 29, 2016

News Daily News

Black Individuals Have Less A-fib, but When They Do, the Consequences Are More Dire

Michael O'Riordan

June 24, 2016

Advertisement

Timing and Dose Matters When It Comes to Statin Therapy Before CABG Surgery

Higher Mortality Among TAVR Patients With Atrial Fibrillation Treated With Triple Therapy

Be It Resolved: How Alcohol Harms or Helps the Heart Remains Controversial—and Confusing

Best Anticoagulant in the TAVR Patient With A-fib? Small Study Makes Case for Apixaban

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Repaso del Año: Los Médicos Eligen las Noticias Más Importantes de 2016 en Cardiología Intervencionista y Más

Avoid Simvastatin, Lovastatin in Dabigatran-Treated Patients, Analysis Suggests

PIONEER Trial: An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy

Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI

FDA: ROCKET AF Results Not Affected by Faulty INR Testing in Warfarin Arm

Addition of Biomarkers May Fine Tune Risk Stratification in Atrial Fibrillation

NOACs as Effective as Warfarin for Reducing Stroke, but Apixaban and Dabigatran May Carry Lower Bleeding Risk: Registry

Increased Risk of In-Hospital Complications, Including Mortality, Among A-fib Patients Undergoing PCI

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Study Provides More Evidence That Having A-fib Ups Risk of Developing Dementia

New A-fib Performance and Quality Measures Emphasize Shared Decision-Making, Inpatient and Outpatient Care

Black Individuals Have Less A-fib, but When They Do, the Consequences Are More Dire

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content